Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARWR
CUSIPN/A
Phone626-304-3400
Debt
Debt-to-Equity Ratio0.02
Current Ratio10.16
Quick Ratio10.16
Price-To-Earnings
Trailing P/E Ratio-27.87
Forward P/E Ratio-17.62
P/E GrowthN/A
Sales & Book Value
Annual Sales$31.41 million
Price / Sales36.36
Cash FlowN/A
Price / CashN/A
Book Value$1.08 per share
Price / Book12.07
Profitability
EPS (Most Recent Fiscal Year)($0.47)
Net Income$-34,380,000.00
Net Margins-199.55%
Return on Equity-50.05%
Return on Assets-40.83%
Miscellaneous
Employees93
Outstanding Shares87,580,000
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions
What is Arrowhead Pharmaceuticals' stock symbol?
Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."
How were Arrowhead Pharmaceuticals' earnings last quarter?
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.18) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.19) by $0.01. The biotechnology company had revenue of $0.65 million for the quarter, compared to analysts' expectations of $4.04 million. Arrowhead Pharmaceuticals had a negative net margin of 199.55% and a negative return on equity of 50.05%. View Arrowhead Pharmaceuticals' Earnings History.
When is Arrowhead Pharmaceuticals' next earnings date?
What price target have analysts set for ARWR?
6 Wall Street analysts have issued twelve-month target prices for Arrowhead Pharmaceuticals' shares. Their forecasts range from $4.00 to $13.00. On average, they anticipate Arrowhead Pharmaceuticals' stock price to reach $9.4467 in the next twelve months. View Analyst Ratings for Arrowhead Pharmaceuticals.
What are Wall Street analysts saying about Arrowhead Pharmaceuticals stock?
Here are some recent quotes from research analysts about Arrowhead Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and $13 PT for the completed enrollment of the Phase 1 trial of ARO-AAT for the treatment of Alpha-1 liver disease. We are encouraged by the impressive execution and rapid enrollment of 44 patients in approximately three months." (6/18/2018)
- 2. Chardan Capital analysts commented, "We believe that Arrowhead is positioned to achieve a number of significant milestones in 2018. The Company spent most of 2017 quietly regrouping following its announcement in November 2016 that it was discontinuing all of its clinical RNAi programs (ARC-520, ARC-521, and ARC-AAT), which use its dynamic polyconjugate (DPC) delivery technology. The decision to discontinue development of these programs was based on the substantial delays that would have occurred in order to further explore the cause of deaths in a non-clinical toxicology study in non-human primates. Arrowhead subsequently reduced its workforce by approximately 30%. In September 2017, the Company unveiled its new proprietary delivery technology they call Targeted RNAi Molecule (TRiM), along with a portfolio of newly named candidates. Arrowhead’s TRiM delivery technology leverages advances in RNA chemistry and targeting, to deliver a payload with increased potency." (2/19/2018)
Who are some of Arrowhead Pharmaceuticals' key competitors?
Some companies that are related to Arrowhead Pharmaceuticals include Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH), Ultragenyx Pharmaceutical (RARE), HUTCHISON CHINA/S (HCM), Array Biopharma (ARRY), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Horizon Pharma (HZNP), Supernus Pharmaceuticals (SUPN), Portola Pharmaceuticals (PTLA), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND) and The Medicines (MDCO).
Who are Arrowhead Pharmaceuticals' key executives?
Arrowhead Pharmaceuticals' management team includes the folowing people:
- Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 49)
- Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 52)
- Dr. Bruce D. Given, Chief Operating Officer (Age 64)
- Mr. Patrick O'Brien, Gen. Counsel (Age 54)
- Dr. Mark M. Davis Ph.D., Founder and Founder & Director of Insert Therapeutics Inc & Calando
Has Arrowhead Pharmaceuticals been receiving favorable news coverage?
Press coverage about ARWR stock has trended somewhat positive this week, Accern reports. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arrowhead Pharmaceuticals earned a daily sentiment score of 0.15 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 44.68 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Arrowhead Pharmaceuticals' major shareholders?
Arrowhead Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include OppenheimerFunds Inc. (8.91%), RTW INVESTMENTS, LP (5.02%), BlackRock Inc. (3.92%), Acuta Capital Partners LLC (2.01%), Nexthera Capital LP (1.27%) and Millennium Management LLC (0.93%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given and Kenneth Allen Myszkowski. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.
Which major investors are selling Arrowhead Pharmaceuticals stock?
ARWR stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, A.R.T. Advisors LLC, Alpine Global Management LLC and Barclays PLC. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given and Kenneth Allen Myszkowski. View Insider Buying and Selling for Arrowhead Pharmaceuticals.
Which major investors are buying Arrowhead Pharmaceuticals stock?
ARWR stock was bought by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, OppenheimerFunds Inc., Nexthera Capital LP, BlackRock Inc., Iguana Healthcare Management LLC, UBS Group AG, Tibra Equities Europe Ltd and GSA Capital Partners LLP. View Insider Buying and Selling for Arrowhead Pharmaceuticals.
How do I buy shares of Arrowhead Pharmaceuticals?
Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arrowhead Pharmaceuticals' stock price today?
One share of ARWR stock can currently be purchased for approximately $13.06.
How big of a company is Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals has a market capitalization of $1.23 billion and generates $31.41 million in revenue each year. The biotechnology company earns $-34,380,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Arrowhead Pharmaceuticals employs 93 workers across the globe.
How can I contact Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]
MarketBeat Community Rating for Arrowhead Pharmaceuticals (ARWR)
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days.
